Comparative efficacy and safety of dolutegravir/lamivudine versus ainuovirine-based triple therapy in people living with HIV: a real-world cohort study
This real-world cohort study demonstrates that while dolutegravir/lamivudine and ainuovirine-based triple therapy offer comparable virological efficacy and immunological recovery in people living with HIV, they differ in their metabolic and renal safety profiles, underscoring the need for individualized treatment selection based on patient-specific risk factors.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the human body as a bustling, high-tech city. For decades, the virus known as HIV has been a relentless saboteur, sneaking into the city's power grid (the immune system) and shutting down the lights. The goal of modern medicine is to keep the city running smoothly by using a special team of "security guards" called antiretroviral therapy (ART). These guards don't just patch holes; they lock the saboteur out completely, allowing the city's population (immune cells) to recover and thrive. But here's the catch: just like any long-term security system, these drugs can have side effects. Some might clog the pipes (kidneys), while others might make the city's fuel supply (cholesterol and weight) get a bit messy. As people with HIV are living longer and healthier lives, doctors are no longer just asking, "Does the virus stop?" They are asking, "Does the treatment keep the whole city healthy for the next 50 years?" This is the big question: can we find a treatment that is just as good at stopping the virus but gentler on the body's long-term health?
This study is like a real-world traffic report comparing two different routes to keep HIV in check. The researchers at Zhenjiang Third People's Hospital looked at 216 people living with HIV who had been driving down one of two roads for at least a year. The first road was a "two-car convoy" called DTG/3TC (dolutegravir and lamivudine). The second road was a "three-car convoy" called ANV/3TC/TDF (ainuovirine, lamivudine, and tenofovir). The scientists wanted to see which convoy got the virus to stop moving (viral suppression) and which one kept the passengers (the patients) feeling better in the long run.
The results show that both routes are excellent at their main job. After 12 months, the "two-car convoy" (DTG/3TC) successfully stopped the virus in 94.45% of passengers, while the "three-car convoy" (ANV/3TC/TDF) did so for 84.45% of passengers. The difference wasn't big enough to say one route was clearly better at stopping the virus; both were highly effective. Both groups also saw their immune systems bounce back, with their "security guard" counts (CD4 cells) rising significantly, and the ratio of good guards to bad ones improving in both groups.
However, the journey wasn't identical for everyone. The "two-car convoy" (DTG/3TC) seemed to have a slightly bumpy ride regarding the body's fuel and plumbing. Passengers on this route showed higher levels of "bad fuel" (LDL cholesterol, total cholesterol, and non-HDL cholesterol) and a slight bump in the "plumbing pressure gauge" (serum creatinine). It's important to note that this bump in creatinine is often a harmless glitch caused by the drug slowing down how the kidneys filter a specific waste product, rather than actual damage to the kidneys. Meanwhile, the "three-car convoy" (ANV/3TC/TDF) kept the fuel levels a bit more stable and the plumbing pressure lower, though it didn't show the same boost in the "good fuel" (HDL cholesterol) that the two-car group did. Interestingly, neither route caused any major issues with the liver, and neither made passengers gain or lose significant weight over the year.
So, what's the takeaway? If you are building a long-term plan, the "two-car convoy" is a powerful, simplified option that works just as well as the traditional "three-car convoy" at stopping the virus. However, because it tends to nudge cholesterol levels up and tweak kidney markers, doctors might want to check the "fuel gauges" and "plumbing" more closely for people on this route. The study suggests that the best choice depends on the individual: if a person is worried about their cholesterol or kidney health, the "three-car convoy" might be the safer bet, but if they want a simpler regimen and their metabolism is robust, the "two-car convoy" is a fantastic, effective alternative. It's not about one being a magic cure-all; it's about picking the right vehicle for the specific passenger.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.